Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Author
Jones, S.
Statsenko, G.
Voitko, O.
Conev, N. V.
Bondarenko, I.
Spencer, S.
Xie, M.
Franks, A.
Paz-Ares, L.
Shrestha, Y.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Reinmuth, N.
Hotta, K.
Poltoratskiy, A.
Trukhin, D.
Hochmair, M. J.
ÖZGÜROĞLU, Mustafa
Ji, J. H.
Metadata
Show full item recordCollections
- Bildiri [64839]